182 related articles for article (PubMed ID: 26987536)
1. Pharmacogenetic Predictors of Response.
Hertz DL; Rae JM
Adv Exp Med Biol; 2016; 882():191-215. PubMed ID: 26987536
[TBL] [Abstract][Full Text] [Related]
2. The Evolving Landscape of HER2 Targeting in Breast Cancer.
Moasser MM; Krop IE
JAMA Oncol; 2015 Nov; 1(8):1154-61. PubMed ID: 26204261
[TBL] [Abstract][Full Text] [Related]
3. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetics and breast cancer management: current status and perspectives.
Ciccolini J; Fanciullino R; Serdjebi C; Milano G
Expert Opin Drug Metab Toxicol; 2015 May; 11(5):719-29. PubMed ID: 25690018
[TBL] [Abstract][Full Text] [Related]
5. Genomic profiling guides the choice of molecular targeted therapy of pancreatic cancer.
Frank TS; Sun X; Zhang Y; Yang J; Fisher WE; Gingras MC; Li M
Cancer Lett; 2015 Jul; 363(1):1-6. PubMed ID: 25890222
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetics and pharmacogenomics as tools in cancer therapy.
Rodríguez-Vicente AE; Lumbreras E; Hernández JM; Martín M; Calles A; Otín CL; Algarra SM; Páez D; Taron M
Drug Metab Pers Ther; 2016 Mar; 31(1):25-34. PubMed ID: 26863347
[TBL] [Abstract][Full Text] [Related]
7. Germline genetic variation, cancer outcome, and pharmacogenetics.
Coate L; Cuffe S; Horgan A; Hung RJ; Christiani D; Liu G
J Clin Oncol; 2010 Sep; 28(26):4029-37. PubMed ID: 20679599
[TBL] [Abstract][Full Text] [Related]
8. Clinical and molecular aspects of breast cancer: Targets and therapies.
Godone RLN; Leitão GM; Araújo NB; Castelletti CHM; Lima-Filho JL; Martins DBG
Biomed Pharmacother; 2018 Oct; 106():14-34. PubMed ID: 29945114
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetics of breast cancer therapies.
Hertz DL; McLeod HL; Hoskins JM
Breast; 2009 Oct; 18 Suppl 3():S59-63. PubMed ID: 19914545
[TBL] [Abstract][Full Text] [Related]
10. Intratumor Heterogeneity in Breast Cancer.
Beca F; Polyak K
Adv Exp Med Biol; 2016; 882():169-89. PubMed ID: 26987535
[TBL] [Abstract][Full Text] [Related]
11. Precision Medicine and Targeted Therapies in Breast Cancer.
Greenwalt I; Zaza N; Das S; Li BD
Surg Oncol Clin N Am; 2020 Jan; 29(1):51-62. PubMed ID: 31757313
[TBL] [Abstract][Full Text] [Related]
12. Precision and predictive medicine in urothelial cancer: are we making progress?
Bellmunt J; Orsola A; Sonpavde G
Eur Urol; 2015 Oct; 68(4):547-9. PubMed ID: 25935702
[TBL] [Abstract][Full Text] [Related]
13. Drug sensitivity testing platforms for gastric cancer diagnostics.
Lau V; Wong AL; Ng C; Mok Y; Lakshmanan M; Yan B
J Clin Pathol; 2016 Feb; 69(2):93-6. PubMed ID: 26567318
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetic and germline prognostic markers of lung cancer.
Horgan AM; Yang B; Azad AK; Amir E; John T; Cescon DW; Wheatley-Price P; Hung RJ; Shepherd FA; Liu G
J Thorac Oncol; 2011 Feb; 6(2):296-304. PubMed ID: 21206385
[TBL] [Abstract][Full Text] [Related]
15. Maurie Markman on the Groundbreaking TAPUR Trial.
Markman M
Oncology (Williston Park); 2017 Mar; 31(3):158, 168. PubMed ID: 28299751
[No Abstract] [Full Text] [Related]
16. Non-HER2 signaling pathways activated in resistance to anti-HER2 therapy in breast cancer.
Madrid-Paredes A; Cañadas-Garre M; Sánchez-Pozo A; Calleja-Hernández MÁ
Breast Cancer Res Treat; 2015 Oct; 153(3):493-505. PubMed ID: 26400847
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy.
De Mattia E; Cecchin E; Toffoli G
Drug Resist Updat; 2015 May; 20():39-70. PubMed ID: 26027741
[TBL] [Abstract][Full Text] [Related]
18. [Pharmacogenetics. Tailored therapy in medicine -- opportunities and challenges].
Scharplatz M; Puhan M; Steurer J; Bachmann LM
Praxis (Bern 1994); 2004 Mar; 93(10):359-65. PubMed ID: 15052854
[TBL] [Abstract][Full Text] [Related]
19. Transformation of alkylating regimen of thiotepa into tepa determines the disease progression through GSTP1 gene polymorphism for metastatic breast cancer patients receiving thiotepa containing salvage chemotherapy.
Zhou X; Wang X; Song Q; Yang H; Zhu X; Yu J; Song G; Di L; Ren J; Shao H; Lyerly HK
Int J Clin Pharmacol Ther; 2015 Nov; 53(11):914-22. PubMed ID: 26396136
[TBL] [Abstract][Full Text] [Related]
20. Targeting PARP in Prostate Cancer: Novelty, Pitfalls, and Promise.
Palmbos PL; Hussain MH
Oncology (Williston Park); 2016 May; 30(5):377-85. PubMed ID: 27188668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]